Top Stories
According to Bloomberg, the pharma is trimming its respiratory and immunology sales teams, though some of the staff are expected to be reassigned within the company.
Integrated analysis finds 89% fewer attacks after lonvo-z treatment in hereditary angioedema (HAE), potentially bolstering the case for long-term efficacy.
The Swiss biotech is developing long-acting respiratory antibodies, while Rezera is focused on oral NLRP3 inhibitors.
The company suggested that decisions on the filings for the oral pyruvate kinase activator are expected in 2027.
The biotech is now targeting a submission for aglatimagene besadenovec in mid-2027, having previously guided for an application this year.
Conference News
SAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company...
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –– Initiation of Phase 3 PROTECT-MS...
—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO® from another prophylactic therapy—RESEARCH TRIANGLE PARK, N.C.,...
A single dose of ZL-1503, across dose levels from 200 to 1,000 mg, produced near-complete (≥90%) inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least 3 monthsExtended serum half-li...
Opinion granted based on positive progression-free survival results from the Phase 3 LITESPARK-011 trialIf approved, this regimen will be the first and only approved combination of a HIF-2α inhibitor ...
